BSX · 8-K · 20261028PR000066
Guidance / Outlook
BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 53 · Surprise 32 · In source text
Boston Scientific estimates full-year 2026 net sales growth of approximately 4.25% reported and 3.75% organic, with adjusted EPS of $3.16 to $3.18. For fourth-quarter 2026, it expects reported and organic net sales to decline approximately 1.0% to 3.0% year over year and adjusted EPS of $0.77 to $0.79. The full-year reported growth estimate includes an approximately 0.5 percentage-point foreign-currency benefit relative to the 3.75% operational growth estimate.
Key facts
- Boston Scientific estimates full-year 2026 reported net sales growth of approximately 4.25% and organic net sales growth of approximately 3.75%. source
- Boston Scientific estimates Q4 2026 net sales will decline approximately 3.0% to 1.0% on both a reported and organic basis versus the prior-year period. source
- Boston Scientific estimates full-year 2026 adjusted EPS, excluding certain charges and credits, of $3.16 to $3.18. source
- Boston Scientific estimates Q4 2026 adjusted EPS, excluding certain charges and credits, of $0.77 to $0.79. source
- Boston Scientific stated that it could not reasonably predict certain items affecting reconciliation of forward-looking adjusted EPS guidance to GAAP, and their combined impact could be material to GAAP financial results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Boston Scientific estimates full-year 2026 reported net sales growth of approximately 4.25% and organic net sales growth of approximately… |
| revenue | negative | committed | — | Boston Scientific estimates Q4 2026 net sales will decline approximately 3.0% to 1.0% on both a reported and organic basis versus the… |